KRAS and lung carcinoma: It was previously reported that the primary mechanism underlying XPO1 inhibitor sensitivity of KRAS-mutant lung cancer cell lines was intolerance to nuclear IκBα accumulation, with consequent inhibition of NF-κB signaling (28).